Bharat Biotech Signs pact with Alopexx for anti-microbial vaccine

Bharat Biotech and Alopexx, Inc. are partnering to develop and sell AV0328, a broad-spectrum anti-microbial vaccine, in India and other low and lower middle-income nations.

A statement from the vaccine manufacturer based in the city mentioned that the companies will work together to develop and sell AV0328, a synthetic vaccine that targets poly N-acetyl glucosamine (PNAG), in India and other authorized regions.

It was stated that Alopexx would receive an initial payment and additional payments upon reaching specific milestones, in addition to royalties from sales of AV0328 in the specified territories.

Krishna Ella, Executive Chairman of Bharat Biotech, said, "We are proud to collaborate with Alopexx to bring AV0328 to the regions where it is most needed. Our goal is to develop solutions to reduce anti-microbial resistance through vaccination. This collaboration aligns with our mission to provide safe, affordable, and high-quality vaccines to combat infectious diseases globally."

"This collaboration brings us one step closer to addressing the critical need for affordable, broad-spectrum antimicrobial solutions, especially in low-and middle-income countries," Daniel Vlock, CEO of Alopexx, said.

Bharat Biotech International Limited, headquartered in Hyderabad, is an Indian multinational biotech firm focused on drug discovery, development, and production of vaccines, biotherapeutics, pharmaceuticals, and healthcare products.